)
Merck (MRK) investor relations material
Merck Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net sales rose 5.8% YoY to €5.627bn, with 5.1% organic growth; EBITDA pre increased 0.8% to €1.682bn. Growth was led by Life Science and Electronics.
FY 2026 guidance was raised for net sales, EBITDA pre and free cash flow, while reported earnings were pressured by a €366m CDMO impairment.
Financial highlights
Q3 reported sales growth comprised 5.1% organic growth, a 1.5-point FX contribution and a 0.8-point negative portfolio effect.
EBITDA pre was €1.682bn versus €1.669bn, up 0.8% reported and 0.4% organically; EPS pre was €2.32, unchanged YoY.
EBIT fell to €653m from €1.221bn; profit after tax was €450m versus €898m, and reported EPS was €1.04 versus €2.07.
Operating cash flow rose 9.4% to €1.660bn and free cash flow increased 22.7% to €1.317bn.
9M sales rose 2.2% to €16.195bn; EBITDA pre increased 3.1% to €4.811bn and EPS pre rose 2.0% to €6.59.
Outlook and guidance
FY 2026 net sales guidance: €21.5bn–€21.9bn, with organic growth of 3%–4% and FX impact of -1% to 0%; EBITDA pre guidance: €6.2bn–€6.4bn, with organic growth of 3%–5%.
EPS pre guidance is €8.30–€8.70; free cash flow guidance increased to €2.3bn–€2.7bn.
Guidance assumes Bio-Techne contributes in December 2026 and no U.S. Mavenclad sales from November; EBITDA pre FX impact is forecast at -2% to 0%.
Segment sales guidance: Life Science €9.4bn–€9.6bn, Healthcare €8.5bn–€8.7bn and Electronics ~€3.6bn; Electronics organic growth guidance is 10%–11%.
FY 2026 capex on PPE is guided at €1.3bn–€1.5bn; the underlying tax rate is expected at 22%–24% from 2027.
- A €0.9bn proposal adds a promising siRNA asset for rare blood cancer.MRK
Acquisition presentation - AI-linked semiconductor demand and Rare Diseases growth supported Q3 as FY26 guidance rose.MRK
Q3 2026 (Media) - Growth fueled by innovation, strategic M&A, and sustainability across all business sectors.MRK
Corporate presentation - Upgraded 2026 guidance as Life Science and Electronics drive growth, with margin expansion.MRK
Q2 2026 - Strong early oncology pipeline progress with promising DDR and ADC assets advancing to clinic.MRK
Investor Update - Q3 2025 delivered robust organic growth, higher margins, and a positive outlook despite FX risks.MRK
Q3 2025 - Growth and margin expansion driven by rare diseases, semiconductor solutions, and innovation.MRK
CMD 2025 - Growth, innovation, and sustainability drive upgraded ambitions and operational excellence.MRK
CMD 2024 - Q1 2025 delivered solid growth and margin gains, with guidance reflecting macro headwinds.MRK
Q1 2025
Next Merck earnings date
Next Merck earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)